title: Oral bropirimine immunotherapy of rodent prostate cancer.
abstract: OBJECTIVE
  Bropirimine is an oral immunostimulant found to have efficacy in human transitional cell carcinoma in situ following the initial discovery of its antitumor activity against the murine bladder cancer MBT-2. To determine if bropirimine might have activity in prostate cancer, it was tested against two rodent prostate cancer cell lines in vivo.
  
  
  METHODS
  Tumors resulted from subcutaneous injection of PAIII and Dunning MAT-LyLu rodent prostate cancer cells. Bropirimine was given at 250 mg/kg orally on different schedules, and tumor volume and survival were recorded.
  
  
  RESULTS
  In the PAIII model, bropirimine prevented growth when given the day of tumor injection, and 95% of advanced tumors regressed completely when start of therapy was delayed. Bropirimine also caused growth inhibition and prolongation of survival in the MAT-LyLu model.
  
  
  CONCLUSIONS
  Bropirimine immunotherapy is very effective in vivo against the PAIII cell line, and it has significant growth inhibition against the Dunning MAT-LyLu cell line.
authors.affiliation: Division of Urology, University of Texas Health Science Center, San Antonio 78284-7845, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Sarosdy
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000627:therapeutic use; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D007167:Immunotherapy / Q000379:methods*; D007369:Interferon Inducers / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007369:Interferon Inducers; D003596:Cytosine; C033560:bropirimine